Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • Learning Objectives After completing this course, the reader will be able to: Describe the mechanisms of action of sorafenib.Discuss the safety and toxicity data from phase I trials of sorafenib.Evaluate phase I and II trials of sorafenib with activity data.Discuss future areas for research in the development of this drug. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Creditâ„¢ at CME.TheOncologist.com

authors

  • Strumberg, Dirk
  • Clark, Jeffrey W
  • Awada, Ahmad
  • Moore, Malcolm J
  • Richly, Heike
  • Hendlisz, Alain
  • Hirte, Holger
  • Eder, Joseph P
  • Lenz, Heinz-Josef
  • Schwartz, Brian

publication date

  • April 1, 2007